BridgeMD
Tests treatment safety and results for Hepatocellular Carcinoma (HCC)
Official title A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
ClinicalTrials.gov ID: NCT07070076
What this study is testing
- What it's testing
- The objective of this clinical trial is to compare the effects of yttrium-90 (SIRT) treatment and hepatic arterial perfusion chemotherapy (HAIC) on progression-free survival (PFS) in patients with potentially resectable HCC in the HCC population. The main questions it aims to answer are: Whether yttrium-90 (SIRT) therapy is more effective than hepatic arterial infusion chemotherapy (HAIC) in treating patients with potentially resectable liver cancer Whether yttrium-90 (SIRT) therapy is safer than hepatic arterial perfusion chemotherapy (HAIC) in patients with potentially resectable liver cancer The researchers compared yttrium-90 (SIRT) treatment to hepatic arterial perfusion chemotherapy (HAIC) to see if yttrium-90 (SIRT) was more effective in treating potentially resectable liver cancer.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age ≥ 18 years and ≤ 75 years.
- Good general condition, with an ECOG Performance Status (PS) of 0-1.
- Classified as China Liver Cancer Staging (CNLC) stage Ib (PS 0-2, Child-Pugh class A/B liver function, single tumor \>5 cm in diameter, without...
- No prior treatment for liver cancer.
- Absence of distant metastasis, with the tumor anticipated to be completely resectable.
You likely can't join if
- Presence of severe impairment of heart, brain, lung, kidney, or other major organ function, severe concurrent infection, or other serious comorbid...
- History of other malignancies.
- History of allergy to related drugs.
- History of organ transplantation.
- Prior treatment for the tumor (including interferon).
- Concurrent HIV infection.
See the full eligibility criteria
- Age ≥ 18 years and ≤ 75 years.
- Good general condition, with an ECOG Performance Status (PS) of 0-1.
- Classified as China Liver Cancer Staging (CNLC) stage Ib (PS 0-2, Child-Pugh class A/B liver function, single tumor \>5 cm in diameter, without radiologically visible vascular tumor thrombus and extrahepatic...
- No prior treatment for liver cancer.
- Absence of distant metastasis, with the tumor anticipated to be completely resectable.
- Patient provides written informed consent after being fully informed about the study.
- Presence of severe impairment of heart, brain, lung, kidney, or other major organ function, severe concurrent infection, or other serious comorbid conditions (\> Grade 2 adverse events per CTCAE Version 4.03), rendering...
- History of other malignancies.
- History of allergy to related drugs.
- History of organ transplantation.
- Prior treatment for the tumor (including interferon).
- Concurrent HIV infection.
- History of drug or substance abuse.
- Occurrence of gastrointestinal bleeding or cardiovascular/cerebrovascular events within approximately 30 days prior to treatment.
- Pregnant or lactating women, or women of childbearing potential unwilling to use contraception.
- Concurrent psychiatric disorders that prevent the patient from providing informed consent or interfere with receiving treatment.
- Any other factors deemed by the investigator as likely to affect patient enrollment or the evaluation of results.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.